Literature DB >> 1320406

Cytomegalovirus and other herpesviruses: do they have a role in the development of accelerated coronary arterial disease in human heart allografts?

T J Kendall1, J E Wilson, S J Radio, R Kandolf, J M Gulizia, G L Winters, M R Costanzo-Nordin, G T Malcom, S L Thieszen, L W Miller.   

Abstract

In conclusion, a great deal of indirect and inferential data point to herpesviruses as having a role in atherogenesis. It has been shown that the herpesviruses are able to remain within vascular tissue in a latent state, allowing for reactivation to occur with subsequent sequelae of an active infection. Herpesviruses affect the cellular metabolic activity of cells, induce the accumulation of lipids, and inhibit the production of matrix proteins. They have the ability to inhibit endothelial cell binding to the basement membrane. It is also known that the herpesviruses, particularly CMV, can initiate a variety of immunologic responses that may contribute to endothelial damage, precipitating atherogenesis. We are only beginning to understand how CMV may participate in ACAD. Greater attention must be focused on the exact cause-and-effect relationship between CMV infection and ACAD. Even the presence of CMV genomes in arterial walls of allografts must be viewed conservatively in the knowledge of CMV ubiquity and other probable contributions to ACAD. If CMV is involved in the development of ACAD, as an active or latent infection, directly or indirectly, it probably involves numerous coexistent mechanisms (Figure 5).

Entities:  

Mesh:

Year:  1992        PMID: 1320406

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  9 in total

1.  An ELISA method to compute endpoint titers to Epstein-Barr virus and cytomegalovirus: application to population-based studies.

Authors:  Raymond P Stowe; R Jeanne Ruiz; Christopher P Fagundes; Robin H Stowe; Min Chen; Ronald Glaser
Journal:  J Immunol Methods       Date:  2014-05-22       Impact factor: 2.303

Review 2.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

Review 3.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 4.  VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy.

Authors:  S Molossi; M Rabinovitch
Journal:  Springer Semin Immunopathol       Date:  1995

5.  Reactivation of herpes simplex virus type 1 is associated with cytomegalovirus and age.

Authors:  Raymond P Stowe; M Kristen Peek; Malcolm P Cutchin; James S Goodwin
Journal:  J Med Virol       Date:  2012-11       Impact factor: 2.327

6.  Questioning the clinical significance of upper gastrointestinal cytomegalovirus disease following heart transplantation.

Authors:  S O Slusser; J P Boehmer; J Zurlo; F Ruggiero; A Ouyang
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

7.  Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts.

Authors:  J M Gulizia; R Kandolf; T J Kendall; S L Thieszen; J E Wilson; S J Radio; M R Costanzo; G L Winters; L L Miller; B M McManus
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

8.  Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells.

Authors:  Yuefei Yu; Petra Pilgrim; Juqiang Yan; Wei Zhou; Marjorie Jenkins; Nicoletta Gagliano; Klaus Bumm; Martin Cannon; Aldo Milzani; Isabella Dalle-Donne; W Martin Kast; Everardo Cobos; Maurizio Chiriva-Internati
Journal:  J Transl Med       Date:  2008-10-05       Impact factor: 5.531

9.  Effects of angiopeptin on transplant arteriosclerosis in the rat.

Authors:  M L Akyürek; A Wanders; M Aurivillius; E Larsson; K Funa; B C Fellström
Journal:  Transpl Int       Date:  1995       Impact factor: 3.782

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.